Dendrosome mediated topical gene silencing by PLK-1 specific siRNA: implication in treatment of skin cancer in mouse model

RSC Advances ◽  
2016 ◽  
Vol 6 (8) ◽  
pp. 6843-6857
Author(s):  
Mohd. Asif Sherwani ◽  
Saba Tufail ◽  
Aijaz Ahmed Khan ◽  
Mohammad Owais
Keyword(s):  
Skin Cancer ◽  
Mouse Model ◽  
Gene Silencing ◽  
Topical Application ◽  
Anti Cancer ◽  
Skin Papillomas

Topical application of PLK-1 siRNA bearing dendrosomes on DMBA induced skin papillomas in mice exhibit potent anti-cancer effect. The treatment leads to reduced number and sizes of papillomas.

Topical gene silencing by iontophoretic delivery of an antisense oligonucleotide–dendrimer nanocomplex: the proof of concept in a skin cancer mouse model

Nanoscale ◽  
2015 ◽  
Vol 7 (9) ◽  
pp. 3903-3914 ◽  
Author(s):  
Venkata Vamsi K. Venuganti, ◽  
Manju Saraswathy ◽  
Chandradhar Dwivedi ◽  
Radhey S. Kaushik ◽  
Omathanu P. Perumal
Keyword(s):  
Skin Cancer ◽  
Mouse Model ◽  
Gene Silencing ◽  
Antisense Oligonucleotide ◽  
Skin Diseases ◽  
Proof Of Concept ◽  
Iontophoretic Delivery

Topical iontophoretic delivery of a dendrimer–antisense oligonucleotide nanocomplex demonstrates the potential for developing gene silencing therapy for skin diseases.

Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer

2008 ◽  
Vol 111 (2) ◽  
pp. 356-364 ◽  
Author(s):  
Amy L. Jonson ◽  
Lisa M. Rogers ◽  
Sundaram Ramakrishnan ◽  
Levi S. Downs
Keyword(s):  
Cervical Cancer ◽  
Mouse Model ◽  
Gene Silencing ◽  
Therapeutic Intervention

scholarly journals Combining chloroquine with RAD001 inhibits tumor growth in a NEN mouse model

2018 ◽  
Vol 25 (6) ◽  
pp. 677-686 ◽  
Author(s):  
Shani Avniel-Polak ◽  
Gil Leibowitz ◽  
Victoria Doviner ◽  
David J Gross ◽  
Simona Grozinsky-Glasberg
Keyword(s):  
Mouse Model ◽  
Tumor Growth ◽  
Mtor Inhibitors ◽  
Degradation Pathway ◽  
Neuroendocrine Neoplasms ◽  
Histopathological Analysis ◽  
Anti Cancer ◽  
Subcutaneous Xenograft ◽  
Rheumatic Drug

Patients with neuroendocrine neoplasms (NENs) often require systemic treatment, which is frequently limited by the emergence of drug resistance. mTOR inhibitors (mTORi), such as RAD001 (everolimus), have been shown to inhibit neoplasm progression. mTORi stimulates autophagy, a degradation pathway that might promote the survival of neoplasm cells that are exposed to anti-cancer therapy. Chloroquine (CQ), a well-known anti-malarial and anti-rheumatic drug, suppresses autophagy. Based on our previous results, we hypothesized that CQ may enhance the anti-tumorigenic effects of mTORi by inhibiting autophagy and we aimed to examine the anti-tumorigenic effect of CQ, alone or in combination with RAD001. We established a NEN subcutaneous xenograft mouse model and evaluated the effect of the drugs on tumor growth, mTOR pathway, autophagy and apoptosis. CQ alone and in combination with RAD001 significantly decreased neoplasm volume. Histopathological analysis revealed that the combination of CQ and RAD001 markedly inhibited mTOR activity and neoplasm cell growth, along with accumulation of autophagosomes and increased apoptosis. In conclusion, CQ enhances the anti-tumorigenic effect of RAD001 in vivo by inhibiting autophagy. Clinical trials addressing the effects of CQ therapy on neoplasm progression in patients with NENs, mainly in those treated with mTORi, are warranted.

scholarly journals MicroRNA-203 represses selection and expansion of oncogenic Hras transformed tumor initiating cells

eLife ◽  
2015 ◽  
Vol 4 ◽  
Author(s):  
Kent Riemondy ◽  
Xiao-jing Wang ◽  
Enrique C Torchia ◽  
Dennis R Roop ◽  
Rui Yi
Keyword(s):  
Cell Division ◽  
Skin Cancer ◽  
Mouse Model ◽  
Mouse Models ◽  
Knockout Mouse ◽  
Selection Process ◽  
Tumor Initiating Cells ◽  
Knockout Mouse Model ◽  
Active Selection ◽  
The Impact

In many mouse models of skin cancer, only a few tumors typically form even though many cells competent for tumorigenesis receive the same oncogenic stimuli. These observations suggest an active selection process for tumor-initiating cells. Here, we use quantitative mRNA- and miR-Seq to determine the impact of HrasG12V on the transcriptome of keratinocytes. We discover that microRNA-203 is downregulated by HrasG12V. Using a knockout mouse model, we demonstrate that loss of microRNA-203 promotes selection and expansion of tumor-initiating cells. Conversely, restoration of microRNA-203 using an inducible model potently inhibits proliferation of these cells. We comprehensively identify microRNA-203 targets required for Hras-initiated tumorigenesis. These targets include critical regulators of the Ras pathway and essential genes required for cell division. This study establishes a role for the loss of microRNA-203 in promoting selection and expansion of Hras mutated cells and identifies a mechanism through which microRNA-203 antagonizes Hras-mediated tumorigenesis.

scholarly journals Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer

2011 ◽  
Vol 9 (1) ◽  
Author(s):  
Natasja K van den Engel ◽  
Dominik Rüttinger ◽  
Margareta Rusan ◽  
Robert Kammerer ◽  
Wolfgang Zimmermann ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Mouse Model ◽  
Tumor Cell ◽  
Combination Immunotherapy ◽  
Cancer Immunity ◽  
Specific Tumor ◽  
Anti Cancer
Sign in / Sign up

Export Citation Format

Share Document